BiDil is the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African-Americans, in the treatment of congestive heart failure. This analysis discusses background issues to help prepare physicians to counsel patients about this controversial drug. BiDil: Assessing a Race-Based PharmaceuticalBy Howard Brody, M.D., Ph.D. [click link for full article]
More...